Open AccessLack of Drug Interactions Between Boosted and Unboosted Tenofovir Alafenamide-Based Antiretroviral Single Tablet Regimens (Emtricitabine/Rilpivirine/Tenofovir Alafenamide and Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide) and the Anti-HCV Single Tablet Regimen Ledipasvir/Sofosbuvir
Author(s) -
Eileen Doyle,
Joseph M. Custodio,
Phillip S. Pang,
Moupali Das,
Huyen Cao,
X. Grace,
Anita Mathias,
Julia Zack
Publication year - 2015
Publication title -
open forum infectious diseases
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.546
H-Index - 35
ISSN - 2328-8957
DOI - 10.1093/ofid/ofv131.80
Subject(s) - cobicistat , tenofovir alafenamide , rilpivirine , medicine , emtricitabine , elvitegravir , virology , pharmacology , human immunodeficiency virus (hiv) , antiretroviral therapy , viral load
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom